Skip to main content
Journal cover image

Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B.

Publication ,  Journal Article
Yogelzang, NJ; Herndon, JE; Cirrincione, C; Harmon, DC; Antman, KH; Corson, JM; Suzuki, Y; Citron, ML; Green, MR
Published in: Cancer
June 1, 1997

BACKGROUND: Malignant mesothelioma is a disease that is refractory to chemotherapy. Therefore, the objective of this multi-institutional, cooperative group Phase II trial was to determine the efficacy of dihydro-5-azacytidine (DHAC), a pyrimidine analogue, in the treatment of malignant mesothelioma. METHODS: Forty-one patients with histologically confirmed malignant mesothelioma received 120-hour continuous infusions of DHAC (1,500 mg/m2/day every 21 days) until maximal response, intolerable toxicity, or disease progression. RESULTS: One patient had a complete response, two had objective partial responses, and four had regression of evaluable disease. The overall response rate was 17%. The one complete responder remains without disease progression at 6 years. Chest pain and nausea were the most common toxicities. Supraventricular tachycardia and pericardial effusion occurred in 20% and 15% of patients, respectively. In most patients, gastrointestinal effects were manageable. There was no significant hematologic toxicity. CONCLUSIONS: In malignant mesothelioma, a disease that is refractory to chemotherapy, dihydro-5-azacytidine has definite antitumor activity. Its modest hematologic toxicity profile favors its use in combination with other agents. Caution regarding cardiac arrhythmias and pericardial effusion is necessary.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Cancer

DOI

ISSN

0008-543X

Publication Date

June 1, 1997

Volume

79

Issue

11

Start / End Page

2237 / 2242

Location

United States

Related Subject Headings

  • Pleural Neoplasms
  • Oncology & Carcinogenesis
  • Middle Aged
  • Mesothelioma
  • Male
  • Humans
  • Female
  • Chest Pain
  • Azacitidine
  • Arrhythmias, Cardiac
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Yogelzang, N. J., Herndon, J. E., Cirrincione, C., Harmon, D. C., Antman, K. H., Corson, J. M., … Green, M. R. (1997). Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B. Cancer, 79(11), 2237–2242. https://doi.org/10.1002/(sici)1097-0142(19970601)79:11<2237::aid-cncr23>3.0.co;2-w
Yogelzang, N. J., J. E. Herndon, C. Cirrincione, D. C. Harmon, K. H. Antman, J. M. Corson, Y. Suzuki, M. L. Citron, and M. R. Green. “Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B.Cancer 79, no. 11 (June 1, 1997): 2237–42. https://doi.org/10.1002/(sici)1097-0142(19970601)79:11<2237::aid-cncr23>3.0.co;2-w.
Yogelzang NJ, Herndon JE, Cirrincione C, Harmon DC, Antman KH, Corson JM, et al. Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B. Cancer. 1997 Jun 1;79(11):2237–42.
Yogelzang, N. J., et al. “Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B.Cancer, vol. 79, no. 11, June 1997, pp. 2237–42. Pubmed, doi:10.1002/(sici)1097-0142(19970601)79:11<2237::aid-cncr23>3.0.co;2-w.
Yogelzang NJ, Herndon JE, Cirrincione C, Harmon DC, Antman KH, Corson JM, Suzuki Y, Citron ML, Green MR. Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B. Cancer. 1997 Jun 1;79(11):2237–2242.
Journal cover image

Published In

Cancer

DOI

ISSN

0008-543X

Publication Date

June 1, 1997

Volume

79

Issue

11

Start / End Page

2237 / 2242

Location

United States

Related Subject Headings

  • Pleural Neoplasms
  • Oncology & Carcinogenesis
  • Middle Aged
  • Mesothelioma
  • Male
  • Humans
  • Female
  • Chest Pain
  • Azacitidine
  • Arrhythmias, Cardiac